DDInter1616 DDInter1376
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Romidepsin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Histrelin
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Romidepsin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Romidepsin may lead to a major life threatening interaction when taken with Halofantrine